Article: Prospective Evaluation of a Fixed-Dose 4-Factor Prothrombin Complex Concentrate Protocol for Urgent Vitamin K Antagonist Reversal.
The Journal of emergency medicine
2019 Volume 58, Issue 2, Page(s) 324–329
Abstract: Background: Four-factor prothrombin complex concentrate (4F-PCC) is the standard of care for reversal of vitamin K antagonists (VKAs). Research has demonstrated noninferior efficacy with the use of lower, fixed-dose strategies for 4F-PCC dosing.: ... ...
| Abstract | Background: Four-factor prothrombin complex concentrate (4F-PCC) is the standard of care for reversal of vitamin K antagonists (VKAs). Research has demonstrated noninferior efficacy with the use of lower, fixed-dose strategies for 4F-PCC dosing. Objectives: We compared a fixed-dose 4F-PCC protocol to weight-based dosing at our institution. Methods: This was a multicenter, noninferiority, interventional, quasiexperimental cohort study including subjects who were administered 4F-PCC for VKA reversal. The retrospective cohort consisted of subjects given a weight-based dose of 4F-PCC dependent on international normalized ratio (INR). The prospective cohort was managed with a fixed-dose protocol. The fixed dose was 1500 units of factor IX unless subjects weighed >100 kg or had a baseline INR >7.5, in which case the dose was 2000 units of factor IX. The primary endpoint was achievement of a postinfusion INR of <2. Secondary endpoints included achievement postinfusion INR <1.5, mean 24-h INR, 7-day mortality, and 7-day venous thromboembolic events. Results: Twenty-four subjects were enrolled in the prospective cohort and 30 in the retrospective cohort. A postinfusion INR <2 was achieved in 96% of subjects in the retrospective cohort and 95% in the prospective cohort (p = 0.0035 for noninferiority). A postinfusion INR <1.5 occurred in 90% of subjects in the retrospective cohort and 75% in the prospective cohort (p > 0.4 for noninferiority). There were no significant differences in 24-h postinfusion INRs, mortality, or venous thromboembolic events. Conclusion: The use of a fixed-dose 4F-PCC protocol is safe and effective for the rapid reversal of VKA-associated anticoagulation. |
|||||
|---|---|---|---|---|---|---|
| MeSH term(s) | Aged ; Anticoagulants/adverse effects ; Anticoagulants/therapeutic use ; Blood Coagulation Factors/administration & dosage ; Emergencies ; Female ; Hemorrhage/chemically induced ; Hemorrhage/drug therapy ; Humans ; Infusions, Intravenous ; International Normalized Ratio ; Male ; Prospective Studies ; Retrospective Studies ; Vitamin K/antagonists & inhibitors | |||||
| Chemical Substances | Anticoagulants ; Blood Coagulation Factors ; Vitamin K (12001-79-5) ; prothrombin complex concentrates (37224-63-8) | |||||
| Language | English | |||||
| Publishing date | 2019-11-29 | |||||
| Publishing country | United States | |||||
| Document type | Comparative Study ; Journal Article ; Multicenter Study | |||||
| ZDB-ID | 605559-x | |||||
| ISSN | 0736-4679 | |||||
| ISSN | 0736-4679 | |||||
| DOI | 10.1016/j.jemermed.2019.10.013 | |||||
| Shelf mark |
|
|||||
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 1895: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.